Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects

NCT07903493 is registered in ClinicalTrials.gov with Mabsoft Therapeutics (Shanghai) Co., Ltd. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07903493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MST-931 in Healthy Adult Subjects
Lead sponsor
Mabsoft Therapeutics (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
November 30, 2026
Completion date
July 30, 2027
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis (as)

Arms

As registered; 5 arms.

  • MST-931 dose level 1 treatment Cohort ExperimentalMST-931

    MST-931 dose level 1

  • MST-931 dose level 2 treatment Cohort ExperimentalMST-931

    MST-931 dose level 2

  • MST-931 dose level 3 treatment Cohort ExperimentalMST-931

    MST-931 dose level 3

  • MST-931 dose level 4 treatment Cohort ExperimentalMST-931

    MST-931 dose level 4

  • Matching placebo for each dose group Placebo comparatorMST-931 Placebo

    Matching placebo

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Percentage of subjects with drug related adverse events (AEs) Through study completion, up to 113 days

Lead sponsor's other trials

Mabsoft Therapeutics (Shanghai) Co., Ltd., most recent start first.

Similar trials

Same condition (Spondylitis, Ankylosing) and phase, most recent start first.